ClinicalTrials.gg
CompletedNCT05395091ALVOBONDUpdated May 29, 2025Results posted

Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND

A Phase 3 interventional study of AVT03 and Denosumab in Osteoporosis, Postmenopausal, sponsored by Alvotech Swiss AG. Completed at 34 sites in 5 countries. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Alvotech Swiss AG · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
532
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Study summary

This is a randomized, double-blind, parallel design, repeat dose, 2 arm, multicenter study comparing the efficacy, safety, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of AVT03 and US-Prolia in postmenopausal women with osteoporosis.

Read the detailed description

After the screening activities, eligible subjects were randomized to receive either AVT03 60 mg or Prolia® 60 mg, administered as a subcutaneous (s.c.) injection on Day 1 and at Month 6. At Month 12, subjects in AVT03 treatment group will received a third dose of AVT03 60 mg administered s.c. while subjects in Prolia® treatment group will were be re-randomized 1:1 to receive either Prolia 60 mg or AVT03 60 mg administered as a subcutaneous injection.

Afterwards, the subjects will be followed until the End of Study (EoS) Visit.

02

Conditions studied

  • Osteoporosis, Postmenopausal

Keywords

  • Postmenopausal Osteoporosis, Denosumab, Alvotech
03

In context

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

This study's enrollment of 532 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.

Browse Osteoporosis, Postmenopausal studies →

Lead sponsor

Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

  1. women with osteoporosis willing to sign an form (ICF)and able to undergo protocol related procedures.
  2. A baseline dual-energy x-ray absorptiometry (DXA) scan with a T score ≤-2.5 and

    • 4.0 at the LS (L1 to L4)and/or, total hip, and/or femoral neck.
  3. Age: ≥50 years.
  4. Female subject is postmenopausal according to 1 of the following criteria:

    1. Spontaneous amenorrhea for ≥12 consecutive months
    2. Biochemical criteria of menopause, follicle-stimulating hormone, >40 IU/L except surgically sterile
    3. Having had bilateral oophorectomy ≥6 weeks prior to Screening
  5. Willing to receive calcium plus vitamin D supplements.
  6. At least 2 consecutive evaluable lumbar vertebrae and at least 1 evaluable hip.

Exclusion Criteria

  1. Evidence of pathology, especially prior diagnosis of bone disease, or any uncontrolled condition that will affect bone metabolism
  2. History and/or presence of 1 severe or more than 1 moderate vertebral fractures confirmed by x-ray.
  3. History of hip fracture
  4. Presence of active healing fractures
  5. Osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures
  6. Evidence of hypo/hypercalcemia at Screening
  7. Known vitamin D deficiency
  8. Known intolerance to calcium and vitamin D supplement.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
532 participants (actual)

Study arms

  • Experimental
    AVT03

    AVT03 is the proposed biosimilar for Prolia.

    Biological: AVT03

  • Active comparator
    Prolia

    Biological: Denosumab

Interventions

  • BiologicalAVT03

    AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL to be administered as a subcutaneous injection. Subjects in this arm received AVT03 60mg administered s.c. on Day 1 and at Month 6. At Month 12, subjects in the AVT03 arm received a third dose of AVT03 60 mg.

  • BiologicalDenosumab

    Prolia (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL developed to be administered as a subcutaneous injection. Subjects in this arm received 60mg of commercially available US-Prolia, administered s.c on Day 1 and at Month 6. At Month 12, subjects in the Prolia treatment group were re-randomized in a 1:1 ratio to receive either: * AVT03 60 mg administered s.c. on Day365. * Prolia 60 mg administered s.c. on Day365.

    Also known as: Prolia

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LS BMD at Month 12 to Demonstrate Comparable Efficacy of AVT03 and Prolia®.

    Percent Change From Baseline in LS BMD at Month 12 to demonstrate comparable efficacy of AVT03 and Prolia®.

    Time frame: Baseline to Month 12

  2. To Demonstrate Comparable Profile of AVT03 and Prolia in Terms of Area Under the Percent Change From Baseline in Serum C-telopeptide of Type 1 Collagen (AUEC of %Cfb sCTX-1)

    Time frame: Baseline to Month 6

Secondary outcomes

  1. Percent Change From Baseline in LS BMD

    Percent change from Baseline in LS BMD at 6 and 18 months

    Time frame: Month 6, Month18

  2. Percent Change From Baseline in Hip and Femoral Neck BMD

    Percent change from Baseline in hip and femoral neck BMD at Month 6, 12 and 18 months

    Time frame: Month 6, Month 12, Month 18

  3. Incidence of New Morphometric Vertebral Fractures

    Incidence of new morphometric vertebral fractures at 12 and 18 months

    Time frame: Month 12 and 18

  4. Percent Change From Baseline in sCTX-1

    Percent change from Baseline in sCTX-1 at 3, 6, 9, 12 and 18 months

    Time frame: Month 3, Month 6, Month 9, Month 12 and Month 18

  5. Incidence, Nature and Severity of Adverse Events Including Adverse Drug Reactions

    Time frame: Month 18

  6. Frequency and Severity of Injection Site Reactions

    Time frame: Month 12

  7. Frequency and Severity of Findings in Routine Safety Parameters

    Time frame: Month 18

  8. Frequency and Titer of Anti-drug Antibodies and Frequency of Neutralizing Antibodies Against AVT03 and Prolia

    Time frame: Month 18

  9. Serum Trough Concentration of AVT03 and Prolia

    Time frame: Month 18

07

Results

Posted May 29, 2025

Participant flow

Baseline to Month 12
Participant flow — Baseline to Month 12
MilestoneAVT03ProliaProlia/AVT03 (Month 12 to Month18)
Started2662660
Completed2422440
Not completed24220
Withdrew: Adverse event720
Withdrew: Death310
Withdrew: Withdrawal by subject11160
Withdrew: Protocol violation230
Withdrew: Physician decision100
Month 12 to Month 18
Participant flow — Month 12 to Month 18
MilestoneAVT03ProliaProlia/AVT03 (Month 12 to Month18)
Started242122122
Completed237120119
Not completed523
Withdrew: Death100
Withdrew: Withdrawal by subject321
Withdrew: Lost to follow-up101
Withdrew: Other reasons001

Outcome measures

PrimaryPercent Change From Baseline in LS BMD at Month 12 to Demonstrate Comparable Efficacy of AVT03 and Prolia®.

Percent Change From Baseline in LS BMD at Month 12 to demonstrate comparable efficacy of AVT03 and Prolia®.

Time frame:
Baseline to Month 12
Reported as:
Least squares mean · Percent Change From Baseline in LS BMD
Percent Change From Baseline in LS BMD at Month 12 to Demonstrate Comparable Efficacy of AVT03 and Prolia®.
Percent Change From Baseline in LS BMDAVT03Prolia
Percent Change From Baseline in LS BMD at Month 12 to Demonstrate Comparable Efficacy of AVT03 and Prolia®.5.3 ± 0.8705.18 ± 0.872
PrimaryTo Demonstrate Comparable Profile of AVT03 and Prolia in Terms of Area Under the Percent Change From Baseline in Serum C-telopeptide of Type 1 Collagen (AUEC of %Cfb sCTX-1)
Time frame:
Baseline to Month 6
Reported as:
Geometric least squares mean · percentage change from baseline*days
To Demonstrate Comparable Profile of AVT03 and Prolia in Terms of Area Under the Percent Change From Baseline in Serum C-telopeptide of Type 1 Collagen (AUEC of %Cfb sCTX-1)
percentage change from baseline*daysAVT03Prolia
To Demonstrate Comparable Profile of AVT03 and Prolia in Terms of Area Under the Percent Change From Baseline in Serum C-telopeptide of Type 1 Collagen (AUEC of %Cfb sCTX-1)2345.55 ± 1.0112342.87 ± 1.011
SecondaryPercent Change From Baseline in LS BMD

Percent change from Baseline in LS BMD at 6 and 18 months

Time frame:
Month 6, Month18

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Hip and Femoral Neck BMD

Percent change from Baseline in hip and femoral neck BMD at Month 6, 12 and 18 months

Time frame:
Month 6, Month 12, Month 18

Results for this outcome have not been posted.

SecondaryIncidence of New Morphometric Vertebral Fractures

Incidence of new morphometric vertebral fractures at 12 and 18 months

Time frame:
Month 12 and 18

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in sCTX-1

Percent change from Baseline in sCTX-1 at 3, 6, 9, 12 and 18 months

Time frame:
Month 3, Month 6, Month 9, Month 12 and Month 18

Results for this outcome have not been posted.

SecondaryIncidence, Nature and Severity of Adverse Events Including Adverse Drug Reactions
Time frame:
Month 18

Results for this outcome have not been posted.

SecondaryFrequency and Severity of Injection Site Reactions
Time frame:
Month 12

Results for this outcome have not been posted.

SecondaryFrequency and Severity of Findings in Routine Safety Parameters
Time frame:
Month 18

Results for this outcome have not been posted.

SecondaryFrequency and Titer of Anti-drug Antibodies and Frequency of Neutralizing Antibodies Against AVT03 and Prolia
Time frame:
Month 18

Results for this outcome have not been posted.

SecondarySerum Trough Concentration of AVT03 and Prolia
Time frame:
Month 18

Results for this outcome have not been posted.

Adverse events

Collected over From baseline to Month 18. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AVT03 (Baseline to Month 12)3/266 (1.1%)9/266 (3.4%)178/266 (66.9%)
Prolia (Baseline to Month 12)1/266 (0.4%)10/266 (3.8%)178/266 (66.9%)
AVT03 (Month 12 to Month18)1/242 (0.4%)6/242 (2.5%)99/242 (40.9%)
Prolia/AVT03 (Month 12 to Month18)0/122 (0%)3/122 (2.5%)39/122 (32%)
Prolia/Prolia (Month 12 to Month18)0/122 (0%)2/122 (1.6%)39/122 (32%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventAVT03 (Baseline to Month 12)Prolia (Baseline to Month 12)AVT03 (Month 12 to Month18)Prolia/AVT03 (Month 12 to Month18)Prolia/Prolia (Month 12 to Month18)
Iron deficiency anaemiaBlood and lymphatic system disorders0/2660/2660/2421/1220/122
Cardiac failure congestiveCardiac disorders0/2660/2660/2420/1221/122
Deafness bilateralEar and labyrinth disorders0/2660/2660/2421/1220/122
CholecystitisHepatobiliary disorders0/2660/2660/2420/1221/122
AppendicitisInfections and infestations0/2661/2660/2420/1221/122
Femur fractureInjury, poisoning and procedural complications0/2660/2660/2421/1220/122
PancytopeniaBlood and lymphatic system disorders0/2660/2661/2420/1220/122
DiplopiaEye disorders0/2660/2661/2420/1220/122
Intestinal obstructionGastrointestinal disorders0/2660/2661/2420/1220/122
Sudden deathGeneral disorders0/2661/2661/2420/1220/122
Most frequent other events
Showing 10 of 305
Most frequent other events
EventAVT03 (Baseline to Month 12)Prolia (Baseline to Month 12)AVT03 (Month 12 to Month18)Prolia/AVT03 (Month 12 to Month18)Prolia/Prolia (Month 12 to Month18)
Upper respiratory tract infectionInfections and infestations32/26636/2667/2421/1228/122
HypocalcaemiaMetabolism and nutrition disorders28/26623/2665/2421/1223/122
NasopharyngitisInfections and infestations23/26620/2669/2423/1222/122
Activated partial thromboplastin time prolongedInvestigations13/26615/2668/2423/1226/122
Urinary tract infectionInfections and infestations14/2665/2663/2423/1223/122
Adjusted calcium decreasedInvestigations14/2666/2668/2424/1220/122
HypertensionVascular disorders12/2668/2662/2420/1222/122
InfluenzaInfections and infestations8/26611/2660/2421/1220/122
Injection site reactionGeneral disorders10/2668/2661/2421/1221/122
ArthralgiaMusculoskeletal and connective tissue disorders10/2669/2663/2420/1220/122

Baseline characteristics

Age, Continuous
Age, Continuous(years)AVT03ProliaTotal
Mean65.2 ± 6.9464.5 ± 7.0464.9 ± 7
Sex: Female, Male
Sex: Female, Male(Participants)AVT03ProliaTotal
Female266266532
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AVT03ProliaTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American131124
White246249495
More than one race202
Unknown or Not Reported5611
Region of Enrollment
Region of Enrollment(participants)AVT03ProliaTotal
Czechia283361
Poland144144288
South Africa474188
Georgia333770
Bulgaria141125
BMI at screening
BMI at screening(kg/m^2)AVT03ProliaTotal
Mean25.12 ± 3.54725.2 ± 3.60525.16 ± 3.573
08

Study locations

34 sites
  • Investigational Site 3501
    Plovdiv, Bulgaria
  • Investigational Site 3503
    Plovdiv, Bulgaria
  • Investigational Site 3502
    Stara Zagora, Bulgaria
  • Investigational Site 4201
    Praha, Czechia
  • Investigational Site 4202
    Uherské Hradiště, Czechia
  • Investigational Site 9901
    Tbilisi, Georgia
  • Investigational Site 9902
    Tbilisi, Georgia
  • Investigational Site 9903
    Tbilisi, Georgia
  • Investigational Site 9904
    Tbilisi, Georgia
  • Investigational Site 9905
    Tbilisi, Georgia
  • Investigational Site 9906
    Tbilisi, Georgia
  • Investigational Site 4803
    Białystok, Poland
  • Investigational Site 4804
    Białystok, Poland
  • Investigational Site 4802
    Kraków, Poland
  • Investigational Site 4807
    Kraków, Poland
  • Investigational Site 4811
    Lublin, Poland
  • Investigational Site 4812
    Poznań, Poland
  • Investigational Site 4801
    Skierniewice, Poland
  • Investigational Site 4809
    Warsaw, Poland
  • Investigational Site 4810
    Zamość, Poland
  • Investigational Site 4806
    Łódź, Poland
  • Investigational Site 4805
    Świdnik, Poland
  • Investigational Site 2705
    Bloemfontein, South Africa
  • Investigational Site 2714
    Cape Town, South Africa
  • Investigational Site 2707
    Centurion, South Africa
  • Investigational Site 2708
    Centurion, South Africa
  • Investigational Site 2710
    Groenkloof, South Africa
  • Investigational Site 2712
    Johannesburg, South Africa
  • Investigational Site 2702
    Kwadukuza, South Africa
  • Investigational Site 2711
    Parow, South Africa
  • Investigational Site 2701
    Port Elizabeth, South Africa
  • Investigational Site 2706
    Pretoria, South Africa
  • Investigational Site 2713
    Pretoria, South Africa
  • Investigational Site 2703
    Worcester, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in May 2024, 20 months.

Results were first posted in May 2025, 1 year after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 20 months is below that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2022
First posted
May 27, 2022
StartActual
Aug 23, 2022
Primary completionActual
May 7, 2024
CompletionActual
Oct 28, 2024
Results first posted
May 29, 2025
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05395091
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
May 27, 2022
Start date
Aug 23, 2022
Primary completion
May 7, 2024
Completion
Oct 28, 2024
Results posted
May 29, 2025
Last update
May 29, 2025

Study contacts

Felicitas Bullo
study director · Alvotech Swiss AG

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AVT03

Start the discussion